Precigen regains exclusive rights to proven car-t targets, cd19 and bcma, to enable unencumbered development and commercialization of ultracar-t®

–  precigen amends exclusive license agreement with alaunos to bolster portfolio and broaden strategic opportunities  – –  the company also regains exclusive rights to il-12 gene therapy, including application through the adenoverse™ platform –  agreement eliminates all future royalties to alaunos – –  precigen to host business and clinical update call on tuesday, april 4, 2023 at 8:30 am et – germantown, md. , april 3, 2023 /prnewswire/ -- precigen, inc. (nasdaq: pgen), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced the amendment of its exclusive license agreement with alaunos therapeutics, inc. (alaunos).
PGEN Ratings Summary
PGEN Quant Ranking